Minerva Neurosciences 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Remy Luthringer

최고 경영자

US$1.8m

총 보상

CEO 급여 비율	34.0%
CEO 임기	10yrs
CEO 소유권	2.6%
경영진 평균 재임 기간	8.6yrs
이사회 평균 재임 기간	9.5yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Remy Luthringer 의 보수는 Minerva Neurosciences 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$3m
Jun 30 2024	n/a	n/a	-US$34m
Mar 31 2024	n/a	n/a	-US$32m
Dec 31 2023	US$2m	US$624k	-US$30m
Sep 30 2023	n/a	n/a	-US$28m
Jun 30 2023	n/a	n/a	-US$27m
Mar 31 2023	n/a	n/a	-US$29m
Dec 31 2022	US$1m	US$600k	-US$32m
Sep 30 2022	n/a	n/a	-US$47m
Jun 30 2022	n/a	n/a	-US$49m
Mar 31 2022	n/a	n/a	-US$51m
Dec 31 2021	US$1m	US$585k	-US$50m
Sep 30 2021	n/a	n/a	-US$36m
Jun 30 2021	n/a	n/a	-US$35m
Mar 31 2021	n/a	n/a	US$5m
Dec 31 2020	US$2m	US$565k	US$2m
Sep 30 2020	n/a	n/a	-US$21m
Jun 30 2020	n/a	n/a	-US$27m
Mar 31 2020	n/a	n/a	-US$69m
Dec 31 2019	US$1m	US$543k	-US$72m
Sep 30 2019	n/a	n/a	-US$55m
Jun 30 2019	n/a	n/a	-US$54m
Mar 31 2019	n/a	n/a	-US$54m
Dec 31 2018	US$4m	US$525k	-US$50m
Sep 30 2018	n/a	n/a	-US$37m
Jun 30 2018	n/a	n/a	-US$36m
Mar 31 2018	n/a	n/a	-US$33m
Dec 31 2017	US$2m	US$445k	-US$32m

보상 대 시장: Remy 의 총 보상 ($USD 1.84M )은 German 시장( $USD 476.59K ).

보상과 수익: 회사가 수익성이 없는 동안 Remy 의 보상이 증가했습니다.

CEO

Remy Luthringer (63 yo)

10yrs

테뉴어

US$1,835,160

보상

Dr. Remy Luthringer, Ph D., serves as a Clinical Advisor to the Medicxi investment team and a Member of the Co-Founding team at Medicxi Ventures (UK) LLP. He has played an active role in several Index Vent...

리더십 팀

이름	위치	테뉴어	보상	소유권
Remy Luthringer	Executive Chairman & CEO	10yrs	US$1.84m	2.64% € 376.5k
Geoffrey Race	President	3.1yrs	US$1.40m	0.73% € 104.6k
Frederick Ahlholm	Senior VP	3.1yrs	US$965.12k	0.25% € 35.7k
Joseph Reilly	Senior VP & COO	10.3yrs	US$1.49m	데이터 없음
William Boni	Vice President of Investor Relations & Corporate Communications	9.3yrs	데이터 없음	데이터 없음
Michael Davidson	Chief Medical Officer	7.9yrs	US$657.47k	데이터 없음

8.6yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 관리: 4MNA 의 관리팀은 노련하고 경험 (평균 재직 기간 8.6 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Remy Luthringer	Executive Chairman & CEO	10yrs	US$1.84m	2.64% € 376.5k
G. van Heek	Independent Director	10.3yrs	US$120.75k	0.036% € 5.2k
Hans Hasler	Independent Director	6.9yrs	US$127.00k	0.018% € 2.5k
David Kupfer	Lead Independent Director	9yrs	US$125.25k	0.34% € 48.8k
Fouzia Laghrissi-Thode	Independent Director	9.5yrs	US$122.25k	0% € 0

9.5yrs

평균 재임 기간

68yo

평균 연령

경험이 풍부한 이사회: 4MNA 의 이사회는 경험(평균 재직 기간 9.5 년)으로 간주됩니다.

Minerva Neurosciences 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Minerva Neurosciences, Inc., Annual General Meeting, Dec 05, 2024

Minerva Neurosciences, Inc., Annual General Meeting, Sep 27, 2023

Minerva Neurosciences, Inc. Announces Board Changes

Insufficient new directors

Recent updates

Minerva Neurosciences, Inc., Annual General Meeting, Dec 05, 2024

Minerva Neurosciences Receives Second Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Listed Securities Requirement under Nasdaq Listing Rule 5550(b)(2)

Minerva Neurosciences Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Listed Securities Requirement Nasdaq's Listing Rule 5550(b)(2)

Minerva Neurosciences, Inc., Annual General Meeting, Sep 27, 2023

Minerva Neurosciences, Inc. announced that it expects to receive $19.999994 million in funding from Frazier Healthcare Partners, Boehringer Ingelheim International GmbH

Nasdaq Determines to Delist Minerva Neurosciences' Securities from The Nasdaq Capital Market

Minerva Neurosciences, Inc. to Report Q1, 2023 Results on May 15, 2023

Minerva Neurosciences, Inc. Announces Board Changes

Minerva Neurosciences, Inc. Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Minerva Neurosciences Receives Non-Compliance Notice from The Nasdaq Stock Market LLC

Minerva Neurosciences, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Minerva Neurosciences, Inc. Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Minerva Neurosciences, Inc. Submits New Drug Application to Fda for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

Insufficient new directors

Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Minerva Neurosciences, Inc. Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin

Investor sentiment deteriorated over the past week

Minerva Neurosciences, Inc.(NasdaqGM:NERV) dropped from Russell 3000E Growth Index

Investor sentiment improved over the past week

Minerva Neurosciences, Inc. Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Following the Completion of the 40-Week Open-Label Extension

Investor sentiment improved over the past week

Revenue misses expectations

Minerva Neurosciences, Inc. to Report Q4, 2020 Results on Mar 08, 2021

Bernstein Liebhard LLP Reminds Investors in SPLK, NAK, and NERV of Filing Deadlines

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Minerva Neurosciences, Inc

New 90-day low: €1.98

Block & Leviton LLP Announces That It Has Filed A Lawsuit Against Minerva Neurosciences, Inc. for Securities Fraud

New 90-day high: €3.00

Minerva Neurosciences, Inc. to Report Q3, 2020 Results on Nov 02, 2020

New 90-day low - €2.32

New 90-day low - €2.68

Minerva Neurosciences, Inc.(NasdaqGM:NERV) dropped from Russell Microcap Value Index

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령